Ehave, Inc. and Identity Key Announce Partnership for Blockchain Based Identity Verification Software for the Medical Industry

MIAMI, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced today it has entered into a partnership (the "Agreement") with Identity Key to provide blockchain based identity verification software for the medical industry. The Agreement calls for the Identity Based Plug-in to be integrated into Ehave’s Dashboard. Ehave will generate royalty revenue based on sales of identity verification software from Identity Key. Ehave currently has products in development that focus on telemedicine, providing medical data, and regulated substance research for mental health. Identity Key is a software company that focuses on creating verifiable credentials for users through the blockchain. Blockchain technology is creating huge opportunities for patients, doctors, and researchers to access data in new ways with audit trails and verifiable authentication.

"Online ID verification is seeing a spike in demand driven by the current pandemic. As many medical professionals send their staff to work remotely during the pandemic there has been a strong surge in demand for videoconferencing communication. Patient identification and verification is one of the most difficult issues the healthcare sector faces during these turbulent times, but it is critical in imparting fast and effective healthcare services to patients,” said Ben Kaplan, Chief Executive officer of Ehave. Mr. Kaplan continued, "Our research indicates digital identity verification systems can benefit healthcare providers by improving the quality of healthcare they provide. We see this opportunity to provide the blockchain based identity verification software from Identity Key to the medical industry as a means to enable them to improve organization and sharing of medical records, ensure insurance claims and reduce medical fraud by protecting patient data."

According to MarketsandMarkets™ Research Private Ltd., "The post-COVID 19 global identity verification market size is expected to grow from USD 7.6 billion in 2020 to USD 15.8 billion by 2025, at a Compound Annual Growth Rate (CAGR) of 15.6% during the forecast period. The major factors fueling the identity verification market include increasing digitization initiatives, increase in fraudulent activities and identity theft during the last decade and increasing use cases of digital identities among verticals."1

“Making each person the center of their data has some exciting benefits,” said Adam Lambert founder of Identity Key. “Decentralized identity, puts patients in control of the entirety of their medical data, sharing only what is needed, when, and with whom.”

Identity Key technology provides a way to verify the source of information (Issuer) by establishing a unique, secure, direct line of communication between a data holder (Patient) and a data verifier (Recipient). This provides a layer of trust while preserving privacy and ensuring data protection.

Attestations about personally identifiable information are trusted, as they are digitally signed by a trusted issuer and can be verified cryptographically, without any data mediators.

Ehave plans to target patients, doctors, and researchers to help them quickly authenticate or release personal, verified data and give more control in situations where trust cannot be compromised. Utilizing the blockchain technology Ehave can offer its medical partners an opportunity to lower their administration costs by up to 90%. Ehave intends to offer its medical partners identity management solutions that include:

 - Verifying Patient Data prior to telemedicine.

 - Allowing the patient to control access to their medical files.

 - Allow partners to verify medical insurance faster.

 - Allow patients to share parts of their health information but maintain privacy.

By verifying patients, doctors, and medical partners faster and more securely, Ehave should be able to offer a significant savings on administration costs. This creates a very secure tool that ensures a more secure verification process and increase profits for medical professionals by lowering the cost of revenue.

Additional Ehave Inc. Statement

We are truly grateful for the patience and support of EHVVF shareholders! Please join the conversation on our Ehave supporter’s telegram group at

The company diligently posts important information and updates through weekly videos from the official company YouTube channel

About Ehave, Inc.

Ehave, Inc. (EHVVF) is a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. Our main product is the Ehave Telemetry Portal, which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights. The Ehave Infinity Portal offers a powerful machine learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools. For more information visit:

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website,

For Investor Relations, please contact:

Gabe Rodriguez

Phone: (623) 261-9046



Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.